D-Phenylalanine

D-Phenylalanine

SCHEMBL503309

C.N[C@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 4/20 0.96
PTGS1 P23219 2/20 0.96
ALPI P09923 1/20 0.96
PKM P14618 1/20 0.96
XIAP P98170 1/20 0.96
SLC1A3 P43003 2/20 0.67
SLC1A2 P43004 2/20 0.67
SLC1A1 P43005 2/20 0.67
SLC15A1 P46059 1/20 0.61
CYP1A2 P05177 1/20 0.59
LTA4H P09960 1/20 0.58
GRIA2 P42262 1/20 0.57
KDM4E B2RXH2 1/20 0.56
USP2 O75604 1/20 0.56
EGFR P00533 1/20 0.56
LCK P06239 1/20 0.56
FYN P06241 1/20 0.56
ADORA3 P0DMS8 1/20 0.56
ALOX15 P16050 1/20 0.56
HTR2A P28223 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dl-Phenylalanine SCHEMBL11103233 1.00 SLC7A5 (0.96) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL503311 1.00 SLC7A5 (0.96) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL1449124 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL8118 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL15671104 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
SCHEMBL23159186 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL1331985 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Phenylalanine SCHEMBL16398197 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
D-Phenylalanine SCHEMBL837632 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP
Dl-Phenylalanine SCHEMBL385804 0.98 SLC7A5 (1.00) SLC7A5PTGS1ALPIPKMXIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 270 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092091-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE LIGANDS Humanwell Pharmaceutical US 2025-03-20 US claimed
US-11976137-B2 Compounds for use as apelin receptor antagonists CAMBRIDGE ENTERPRISE LIMITED (GB) 2024-05-07 US claimed
CN-114615976-A Kappa opioid receptor peptide amide agonists 人福医药美国公司 2022-06-10 CN claimed
US-20210155659-A1 COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS CAMBRIDGE ENTERPRISE LIMITED (GB) 2021-05-27 US claimed
EP-3773663-A1 COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS Cambridge Enterprise Limited (GB) 2021-02-17 EP claimed
WO-2021026492-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS Humanwell Pharmaceutical US (US) 2021-02-11 WO claimed
US-20210040150-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) 2021-02-11 US claimed
CN-112165953-A Compounds useful as apelin receptor antagonists 剑桥企业有限公司 2021-01-01 CN claimed
WO-2019193355-A1 COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS DAVENPORT ANTHONY PETER (GB) 2019-10-10 WO claimed
CN-120202010-A Ligand-oligonucleotide conjugates and linkers for use therewith 上海京新生物医药有限公司 2025-06-24 CN disclosed
US-20250092091-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE LIGANDS Humanwell Pharmaceutical US 2025-03-20 US disclosed
EP-4504732-A2 NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF University of Connecticut (US) 2025-02-12 EP disclosed
US-12215173-B2 Kappa opioid receptor peptide amide ligands HUMANWELL PHARMACEUTICAL US, Inc. (US) 2025-02-04 US disclosed
CN-118879592-A Unnatural base pair compositions and methods of use 斯克利普斯研究所 2024-11-01 CN disclosed
WO-2008022444-A1 SMALL CATIONIC ANTIMICROBIAL PEPTIDES THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2008-02-28 WO disclosed
EP-1740559-A4 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO INC (US) 2007-12-12 EP disclosed
US-20070244119-A1 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease MERCK SHARP & DOHME LLC 2007-10-18 US disclosed
CN-1942457-A 1,3, 5-substituted phenyl derivative compounds as beta-secretase inhibitors for the treatment of alzheimer's disease MERCK & CO INC (US) 2007-04-04 CN disclosed
EP-1740559-A1 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Merck & Co., Inc. (US) 2007-01-10 EP disclosed
WO-2005103020-A1 1,3,5-SUBSTITUTED PHENYL DERIVATIVE COMPOUNDS USEFUL AS BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE MERCK & CO., INC. (US) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11976137-B2 Compounds for use as apelin receptor antagonists APLNR, GIPR, GRPR SLC7A5 2343/4885PTGS1 1137/4885ALPI 1061/4885
US-20250092091-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE LIGANDS OPRK1, OPRL1, OPRD1 SLC7A5 3117/4885PTGS1 696/4885ALPI 3220/4885
US-20070244119-A1 1,3,5-Substituted Phenyl Derivative Compounds Useful as Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease BACE1, BACE2, PSEN1 SLC7A5 3571/4885PTGS1 714/4885ALPI 1771/4885
US-20210155659-A1 COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS APLNR, GIPR, GRPR SLC7A5 2343/4885PTGS1 1137/4885ALPI 1061/4885
US-12215173-B2 Kappa opioid receptor peptide amide ligands OPRK1, OPRL1, OPRD1 SLC7A5 3117/4885PTGS1 696/4885ALPI 3220/4885
US-20210040150-A1 KAPPA OPIOID RECEPTOR PEPTIDE AMIDE AGONISTS OPRK1, OPRL1, OPRD1 SLC7A5 3240/4885PTGS1 651/4885ALPI 2960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.